Analyst Tycho Peterson of Jefferies reiterated a Buy rating on Labcorp Holdings, with a price target of $300.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tycho Peterson has given his Buy rating due to a combination of factors that highlight Labcorp Holdings’ strong financial performance and promising outlook. The company reported a 1% top-line beat, driven by improvements in its Biopharma Lab Services and Diagnostics Laboratories segments. The Biopharma Lab Services segment showed a 6% revenue beat with significant organic growth, while the Diagnostics Laboratories segment maintained solid performance with a 4.5% organic growth.
Furthermore, Labcorp’s earnings per share exceeded expectations, and the company raised its full-year revenue and earnings guidance, reflecting favorable foreign exchange impacts. The esoteric diagnostics segment is outpacing the market, and the company is strategically positioning itself in oncology. Despite potential policy headwinds, Labcorp’s ability to manage these challenges and its strong free cash flow conversion support a positive outlook, justifying the Buy rating.
Based on the recent corporate insider activity of 78 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LH in relation to earlier this year.